

Anne Letsch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11428673/publications.pdf>

Version: 2024-02-01

46
papers

1,774
citations

304743

22
h-index

265206

42
g-index

47
all docs

47
docs citations

47
times ranked

2348
citing authors

#	ARTICLE	IF	CITATIONS
1	Information, communication, and cancer patients' trust in the physician: what challenges do we have to face in an era of precision cancer medicine?. Supportive Care in Cancer, 2021, 29, 2171-2178.	2.2	12
2	Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q). Annals of Hematology, 2021, 100, 1463-1471.	1.8	1
3	Psychometric Evaluation of the German Version of the Demoralization Scale-II and the Association Between Demoralization, Sociodemographic, Disease- and Treatment-Related Factors in Patients With Cancer. Frontiers in Psychology, 2021, 12, 789793.	2.1	10
4	Cancer patients' expectations when undergoing extensive molecular diagnostics—A qualitative study. Psycho-Oncology, 2020, 29, 423-429.	2.3	16
5	Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo. Cancer Immunology, Immunotherapy, 2020, 69, 1217-1227.	4.2	8
6	Early palliative care for those who care: A qualitative exploration of cancer caregivers' information needs during hospital stays. European Journal of Cancer Care, 2019, 28, e12990.	1.5	15
7	Early integration of palliative cancer care: patients' and caregivers' challenges, treatment preferences, and knowledge of illness and treatment throughout the cancer trajectory. Supportive Care in Cancer, 2018, 26, 921-931.	2.2	11
8	Early integration of palliative/supportive cancer care—healthcare professionals' perspectives on the support needs of cancer patients and their caregivers across the cancer treatment trajectory. Supportive Care in Cancer, 2017, 25, 1621-1627.	2.2	16
9	Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients. Cancer Immunology, Immunotherapy, 2016, 65, 181-192.	4.2	27
10	Wilms tumor protein 1 (WT1) — Not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma. Gynecologic Oncology, 2016, 140, 494-502.	1.4	26
11	Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy. BMC Cancer, 2015, 15, 784.	2.6	11
12	Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment. Blood, 2015, 126, 2891-2891.	1.4	1
13	Human bone marrow contains a subset of quiescent early memory CD8 ⁺ T cells characterized by high CD127 expression and efflux capacity. European Journal of Immunology, 2014, 44, 3532-3542.	2.9	9
14	TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial. Blood, 2013, 122, 2759-2759.	1.4	0
15	Harmonization of the intracellular cytokine staining assay. Cancer Immunology, Immunotherapy, 2012, 61, 967-978.	4.2	47
16	Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3 ² sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer Immunology, Immunotherapy, 2012, 61, 313-322.	4.2	17
17	Wilms Tumor Protein 1 (WT1) Peptide Vaccination-induced Complete Remission in a Patient With Acute Myeloid Leukemia Is Accompanied by the Emergence of a Predominant T-cell Clone Both in Blood and Bone Marrow. Journal of Immunotherapy, 2011, 34, 85-91.	2.4	24
18	Clinically misinterpreted melanoma metastases can correctly be diagnosed by ultrasound-guided fine needle aspiration cytology. European Journal of Dermatology, 2011, 21, 238-241.	0.6	5

#	ARTICLE	IF	CITATIONS
19	Long term presence of a single predominant tyrosinase-specific T cell clone associated with disease control in a patient with metastatic melanoma. <i>International Journal of Cancer</i> , 2010, 126, 2497-2502.	5.1	4
20	Human peripheral blood and bone marrow Epstein-Barr virus-specific T cell repertoire in latent infection reveals distinct memory T cell subsets. <i>European Journal of Immunology</i> , 2010, 40, 1566-1576.	2.9	32
21	Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination. <i>Journal of Translational Medicine</i> , 2010, 8, 5.	4.4	13
22	Human Bone Marrow as a Source to Generate CMV-specific CD4+ T Cells With Multifunctional Capacity. <i>Journal of Immunotherapy</i> , 2009, 32, 907-913.	2.4	12
23	A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. <i>Blood</i> , 2009, 113, 6541-6548.	1.4	275
24	Identification of truncated chemokine receptor 7 in human colorectal cancer unable to localize to the cell surface and unreactive to external ligands. <i>International Journal of Cancer</i> , 2008, 123, 1565-1572.	5.1	8
25	CMV-specific central memory T cells reside in bone marrow. <i>European Journal of Immunology</i> , 2007, 37, 3063-3068.	2.9	32
26	Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 391-396.	4.2	10
27	Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2. <i>Blood</i> , 2006, 107, 3205-3211.	1.4	40
28	Specific Central Memory T Cells in the Bone Marrow of Patients Immunized Against Tyrosinase Peptides. <i>Journal of Immunotherapy</i> , 2006, 29, 201-207.	2.4	10
29	Identification of a Highly Immunogenic HLA-A*01-Binding T Cell Epitope of WT1. <i>Clinical Cancer Research</i> , 2006, 12, 7476-7482.	7.0	53
30	Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients. <i>International Journal of Cancer</i> , 2005, 114, 936-941.	5.1	16
31	Malignant Melanoma - Clinical Development of Peptide-Based Melanoma Vaccines. , 2005, 39, 171-180.		0
32	T cell responses against tumor associated antigens and prognosis in colorectal cancer patients. <i>Journal of Translational Medicine</i> , 2005, 3, 3.	4.4	23
33	Intracellular Cytokine Staining. , 2005, , 175-182.		3
34	Quantitative Detection of Circulating Tumor Cells in Cutaneous and Ocular Melanoma and Quality Assessment by Real-Time Reverse Transcriptase-Polymerase Chain Reaction. <i>Clinical Cancer Research</i> , 2004, 10, 1605-1612.	7.0	96
35	Functional CCR9 Expression Is Associated with Small Intestinal Metastasis. <i>Journal of Investigative Dermatology</i> , 2004, 122, 685-690.	0.7	84
36	Lymphoma Cells Are Highly Sensitive to Cytotoxic T-Cell-Killing Despite Presence of Multiple Resistance Mechanisms. <i>Journal of Immunotherapy</i> , 2004, 27, S45.	2.4	1

#	ARTICLE	IF	CITATIONS
37	Rational peptide-based tumour vaccine development and T cell monitoring. <i>Seminars in Cancer Biology</i> , 2003, 13, 423-429.	9.6	36
38	Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. <i>International Journal of Cancer</i> , 2003, 104, 188-194.	5.1	74
39	Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients. <i>International Journal of Cancer</i> , 2003, 105, 221-225.	5.1	31
40	Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISPOT assay or intracellular cytokine staining. <i>Methods</i> , 2003, 31, 143-149.	3.8	88
41	Bone marrow contains melanoma-reactive CD8+ effector T cells and, compared with peripheral blood, enriched numbers of melanoma-reactive CD8+ memory T cells. <i>Cancer Research</i> , 2003, 63, 5582-6.	0.9	42
42	Natural T cell immunity against cancer. <i>Clinical Cancer Research</i> , 2003, 9, 4296-303.	7.0	154
43	CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. <i>Blood</i> , 2002, 100, 2132-2137.	1.4	245
44	Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides. <i>International Journal of Cancer</i> , 2002, 99, 403-408.	5.1	26
45	Flow cytometric determination of intracellular or secreted IFN γ for the quantification of antigen reactive T cells. <i>Journal of Immunological Methods</i> , 2001, 251, 101-108.	1.4	67
46	High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma. <i>International Journal of Cancer</i> , 2000, 87, 659-664.	5.1	43